Results 91 to 100 of about 22,921 (208)
Cytomegalovirus Colitis Following Azacitidine Therapy
Canadian Journal of Infectious Diseases and Medical Microbiology, 2011 The present report describes the first recognized case of cytomegalovirus (CMV) colitis following azacitidine therapy. A 66-year-old woman with myelodysplastic syndrome developed CMV colitis, which responded to treatment with ganciclovir.
Rajal Khan +6 more
doaj +1 more source
Anaphylactic transfusion reaction to group B platelets related to alpha‐gal syndrome: A case report
Transfusion, EarlyView.Abstract Background Alpha‐gal syndrome (AGS), a distinct form of IgE‐mediated hypersensitivity to the carbohydrate galactose‐α‐1,3‐galactose (α‐Gal), typically occurs after repeated tick bites and leads to allergic reactions after ingestion of mammalian meat.
Oscar Andre Hinojosa +2 more
wiley +1 more source
eJHaem, Volume 7, Issue 3, June 2026.ABSTRACT Objective To retrospectively analyze the early efficacy and safety of azacitidine plus lisaftoclax in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome with increased blasts (MDS‐IB), providing a reliable clinical reference.
Shan Meng +9 more
wiley +1 more source
Deacetylase inhibitors CM‐444 and CM‐1758 enhance chemotherapy response in AML via ALOX5
British Journal of Haematology, EarlyView.
Naroa Gimenez‐Camino +7 more
wiley +1 more source
Oxidative Stress and DNA Epigenetic Modifications in Cancer: Mechanisms and Targeted Therapeutics
MedComm – Oncology, Volume 5, Issue 2, June 2026.Reactive oxygen species (ROS) modulate DNA methyltransferases (DNMTs), ten‐eleven translocation family proteins (TETs) and their cofactors, reshaping 5‐methylcytosine (5mC)/5‐hydroxymethylcytosine (5hmC)/5‐formylcytosine (5fC) landscapes and gene expression in cancer cells. In turn, epigenetic control of antioxidant and metabolic pathways feeds back on
Xishan Yang +7 more
wiley +1 more source
HaematologicaInfants less than 1 year old diagnosed with KMT2A-rearranged (KMT2A-r) acute lymphoblastic leukemia (ALL) are at high risk of remission failure, relapse, and death due to leukemia, despite intensive therapies. Infant KMT2A-r ALL blasts are characterized
Erin M. Guest +20 more
doaj +1 more source
Targeting EZH2 in Cancer: From Molecular Mechanisms to Clinical Translation
MedComm – Oncology, Volume 5, Issue 2, June 2026.The abnormal overexpression or gain‐of‐function mutations of EZH2 play a significant role in cancer occurrence and progression, highlighting the importance and potential of EZH2 as a cancer biomarker. Therefore, screening for effective and safe small‐molecule inhibitors, degraders, and natural compounds targeting EZH2 through preclinical cancer models ...
Xi Zhong +4 more
wiley +1 more source
Giant cellulitis‐like Sweet's syndrome induced by gilteritinib
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Juan de Luque‐Fernández +5 more
wiley +1 more source
American Journal of Hematology, Volume 101, Issue 5, Page 949-960, May 2026.ABSTRACT The addition of midostaurin (MIDO) to intensive chemotherapy (IC) improves survival in younger adults with FLT3‐mutated acute myeloid leukemia (AML); however, real‐world data in elderly patients (≥ 60 years) are limited. This large, retrospective, multicenter study from three European registries (PETHEMA, FILO, DATAML) evaluated MIDO+IC (n ...
Gaspar Aspas Requena +31 more
wiley +1 more source
Selinexor and Venetoclax Combination in Patients With Relapsed or Refractory Acute Myeloid Leukemia
American Journal of Hematology, Volume 101, Issue 5, Page 1019-1024, May 2026.ABSTRACT Preclinical studies showed a synergistic antileukemia activity with combination of selective XPO1 inhibitor selinexor (SEL) and venetoclax (VEN), with potential to overcome VEN resistance by reducing the anti‐apoptotic protein MCL1. In an investigator‐sponsored, open‐label, phase Ib study (NCT03955783), adult patients with relapsed or ...
Somedeb Ball +11 more
wiley +1 more source